Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.92)
# 47
Out of 5,241 analysts
37
Total ratings
77.42%
Success rate
68.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Downgrades: Neutral | $16 → $24 | $20.56 | +16.73% | 3 | May 15, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $30 → $26 | $13.89 | +87.19% | 3 | May 8, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $120 → $172 | $145.66 | +18.08% | 3 | May 7, 2026 | |
| SMMT Summit Therapeutics | Maintains: Neutral | $17 → $16 | $16.87 | -5.16% | 2 | May 1, 2026 | |
| RLMD Relmada Therapeutics | Initiates: Overweight | $12 | $6.90 | +73.91% | 1 | Mar 24, 2026 | |
| ERAS Erasca | Maintains: Overweight | $11 → $18 | $10.23 | +75.95% | 3 | Mar 13, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $66.93 | +4.59% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.75 | +190.91% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $5.10 | +370.59% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $8.15 | +169.94% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $128 | $102.30 | +25.12% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $28.78 | +25.09% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $20.23 | +77.95% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.34 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.92 | +173.97% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.25 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $27.55 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.45 | - | 1 | Oct 31, 2022 |
Tango Therapeutics
May 15, 2026
Downgrades: Neutral
Price Target: $16 → $24
Current: $20.56
Upside: +16.73%
Janux Therapeutics
May 8, 2026
Maintains: Overweight
Price Target: $30 → $26
Current: $13.89
Upside: +87.19%
Revolution Medicines
May 7, 2026
Maintains: Overweight
Price Target: $120 → $172
Current: $145.66
Upside: +18.08%
Summit Therapeutics
May 1, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $16.87
Upside: -5.16%
Relmada Therapeutics
Mar 24, 2026
Initiates: Overweight
Price Target: $12
Current: $6.90
Upside: +73.91%
Erasca
Mar 13, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $10.23
Upside: +75.95%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $66.93
Upside: +4.59%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.75
Upside: +190.91%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $5.10
Upside: +370.59%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $8.15
Upside: +169.94%
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $102.30
Upside: +25.12%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $28.78
Upside: +25.09%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $20.23
Upside: +77.95%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.34
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.92
Upside: +173.97%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.25
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $27.55
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.45
Upside: -